Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, cancer, endocrine, inflammatory and neurological disorders.

Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.

Kidney stones are largely composed of calcium oxalate (CaOx), which can cause serious renal inflammation and damage to renal tubular epithelial cells, with the CaOx crystals gradually accumulating and leading to CaOx nephrocalcinosis.

A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate receptor in mast cells.

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 (STAT6) program that the Danish dermatology specialist has been working on since 2018.

Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.

Lynk Pharmaceuticals Co. Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.